Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV ferric carboxymaltose for postoperative anaemia after trauma surgery
ACTRN12624000410550Phase 4Active, not recruiting
- Sponsor
- Alfred Health
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, double-blind trial of ferric carboxymaltose in anaemia (2 arms), sponsored by Alfred Health. Primary endpoints: Consent rate, Successful study drug administration and 1 more. Started Jun 2024; status: active, not recruiting.
02
Drugs
ferric carboxymaltose
03
Conditions
anaemia
Beyond the preview
Go deeper on ACTRN12624000410550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000410550.